HSK 39004
Alternative Names: HSK-39004Latest Information Update: 30 May 2025
At a glance
- Originator Haisco Pharmaceutical Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 06 May 2025 Haisco Pharmaceutical completes a phase I trial in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation, Powder) (NCT06971198)
- 20 Mar 2025 Haisco Pharmaceutical completes a phase I trial in Chronic obstructive pulmonary disease in China (Inhalation) (NCT06905847)
- 10 Feb 2025 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation) (NCT06971198)